-
Japan – Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
09 Oct 2025 14:00 GMT
… Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen … Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO … regulative submissions internationally with Eisai and Biogen co- …
-
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
06 Oct 2025 20:30 GMT
… NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen … Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO … Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.
About …
-
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
17 Sep 2025 12:00 GMT
… inhibitor—today announced that its CEO, Thomas Jensen, has been invited … , which was originally developed by Eisai Co. Ltd. and was formerly …
-
CEO and FD ousted from board of listed MedTech
14 Sep 2025 22:55 GMT
MedTechAppointmentsThe CEO and finance director … with a ‘significant’ shareholder, chief executive Andrew Newland and FD Ian … contracts with large pharma companies Eisai and AstraZeneca, while claiming … Turing Institute slammed as CEO resigns
It admitted that …
-
“New Answers to Dementia” Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
14 Sep 2025 17:54 GMT
… – (JCN Newswire) –Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) revealed today … companies throughout Japan that share Eisai’s dedication to supporting dementia … of “Science, Courage, and Perseverance,” Eisai continues to provide “brand-new …
-
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
08 Sep 2025 04:32 GMT
… (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today … ., Chief Scientific Officer at Eisai, commented: "At … orexinergic neuron activity, Eisai has developed the insomnia … fall asleep.
MEDIA CONTACTS:
Eisai Co., Ltd.
Public …
-
Fierce Pharma Asia—Novartis' $5B Argo deal; Eisai's subcutaneous Leqembi nod; HKEX chastises Henlius
05 Sep 2025 22:00 GMT
… approved a subcutaneous version of Eisai and Biogen's … Henlius Biotech and its former CEO over a questionable reallocation … a subcutaneous version of Eisai and Biogen’s Leqembi … week via an autoinjector. Eisai hopes the more convenient formulation …
-
Japan – Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the...
04 Sep 2025 08:00 GMT
… – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen … , Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) revealed today that Eisai has actually …
-
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
04 Sep 2025 01:22 GMT
… PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, … ;Eisai") announced today that … Prospective, Real-world Observational Study
Eisai-Sponsored Symposium: RISE – Regional …
-
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
02 Sep 2025 23:30 GMT
… NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen … , Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated …
About
© 1995-2025